

BEIKE BIOTECHNOLOGY

A Descriptive Statistical Report on 30 Cerebral Palsy Cases with Cell Therapy From 2007, 2008, and 2009

Background

This descriptive report covers subjective information collected by questionnaires from our overseas Cerebral Palsy (CP) patients confirmed before the hospital-admission. Participating patients were treated in 2007, 2008, and 2009. This information mainly includes the efficacy assessment of the cell therapy on four time points: immediately after the treatment, one month, three months and six months after the treatment. The data for this analysis is based solely on patients from 2007-2009 who submitted the questionnaire to our followup department.

Results

Age Structure: The mean age of the participating patients is 8.7 years (SD=8.2). All are CP diagnosed-confirmed patients before coming to China. The age structure is shown in Chart 1 on page two. A majority of patients (73%) are under 10 years old.

General Effectiveness: General effectiveness was measured by a Yes/No question asked to the patient and/or the patient's caregiver. The question asked if the patient had any improvement at any time after the treatment. The general effectiveness percentage is 77.7%. The analysis results by age show that the effectiveness percentage of the under-10 year-old patients (15/22, 68%) is not significantly different compared with that of the above-10 year-old patients (8/8, 100%). (Fisher's Exact Probability Test, $P > 0.05$).

Improvement Immediately After the Treatment: The effectiveness rate at the time point immediately after the treatment is 12 out the 30 patients (40%).

Improvement at 1 Month, 3 Months, and 6 Months: There were five patients at one month, five patients at three months, and one patient at six months after the treatment that received their first improvements at these time points. A representation of these numbers can be seen on page two in Chart 2.

Conclusions

For the 30 patients, the general effectiveness percentage is 77.7% (percent of total patients that received improvement). 12 out of 30 patients received improvements immediately after treatment, while 11 of the 30 patients received their first improvements at least one month after the treatment. 7 out of the 30 patients (23%) did not receive any improvements within a year after the treatment.

Chart 1: Ages of Participating Patients





Chart 1: When Patients First Noticed Improvement (After Treatment)



Disclaimer: The information contained in this document is to be used solely as a reference for observing patients' subjective opinions and observations about treatment efficacy.

BEIKE BIOTECHNOLOGY CO., LTD.
9th Floor, Zhongke Building, 1 South Street
South Area, Shenzhen Hi-Tech Industrial Park
Shenzhen, China 518057

Tel: +86-755-8630-9277 Email: info@beikebiotech.com
Fax: +86-755-8630-9309 Web: www.beikebiotech.com